As a branded drug, Gleevec’s price increases were the target of criticism by oncologists, payers, and patients. Yet, its price was more reflective of value than many other cancer drugs. What is problematic is the fact that generic imatinib’s list price has remained stubbornly high.
The Curious Case Of Gleevec Pricing
